Literature DB >> 9721598

Receptor binding profile of Otilonium bromide.

S Evangelista1, A Giachetti, B Chapelain, G Neliat, C A Maggi.   

Abstract

The interaction of Otilonium bromide (OB) with binding sites for 63 different receptors and ion channels in appropriate preparations has been investigated. Experiments were also performed in rat colon, the preferred tissue for OB 'in vivo' uptake after oral administration. Among the receptors investigated OB binds with sub microM affinity to muscarinic M1, M2, M4, M5 and PAF receptors and with microM affinity to the diltiazem binding site on L type Ca2+ channels. In the rat colon OB shows competitive interaction with the verapamil binding site on L type Ca2+ channels and with muscarinic M2 receptors with IC50 of 1020 and 1220 nM, respectively. These findings provide a molecular rationale to explain the spasmolytic action exerted by OB on intestinal smooth muscle. In particular, a combination of antimuscarinic and Ca2+ channel blocker properties seems to best account for the action of this compound.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721598     DOI: 10.1006/phrs.1998.0340

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  12 in total

1.  Changes in nitrergic and tachykininergic pathways in rat proximal colon in response to chronic treatment with otilonium bromide.

Authors:  G Cipriani; S J Gibbons; S A Saravanaperumal; J Malysz; L Sha; J H Szurszewski; D R Linden; S Evangelista; M S Faussone-Pellegrini; M G Vannucchi; G Farrugia
Journal:  Neurogastroenterol Motil       Date:  2015-04-30       Impact factor: 3.598

Review 2.  Irritable bowel syndrome.

Authors:  Antonella Spinelli
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

3.  The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts.

Authors:  Susanne Lindqvist; James Hernon; Paul Sharp; Neil Johns; Sarah Addison; Mark Watson; Richard Tighe; Shaun Greer; Jean Mackay; Michael Rhodes; Michael Lewis; William Stebbings; Chris Speakman; Stefano Evangelista; Ian Johnson; Mark Williams
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 4.  Recent advances in pharmacological treatment of irritable bowel syndrome.

Authors:  Georgia Lazaraki; Grigoris Chatzimavroudis; Panagiotis Katsinelos
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 5.  Colonic smooth muscle cells and colonic motility patterns as a target for irritable bowel syndrome therapy: mechanisms of action of otilonium bromide.

Authors:  Jakub Rychter; Francisco Espín; Diana Gallego; Patri Vergara; Marcel Jiménez; Pere Clavé
Journal:  Therap Adv Gastroenterol       Date:  2014-07       Impact factor: 4.409

Review 6.  Role of antispasmodics in the treatment of irritable bowel syndrome.

Authors:  Anita Annaházi; Richárd Róka; András Rosztóczy; Tibor Wittmann
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

7.  Preparation and characterization of reconstructed small intestinal brush border membranes for surface plasmon resonance analysis.

Authors:  Sungpil Cho; Jae Hyung Park; Jaehoon Yu; Yong-Kyu Lee; Youngro Byun; Hesson Chung; Ick Chan Kwon; Seo Young Jeong
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

8.  The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome.

Authors:  Full-Young Chang; Ching-Liang Lu; Jiing-Chyuan Luo; Tseng-Shing Chen; Mei-Jung Chen; Hsiu-Ju Chang
Journal:  J Neurogastroenterol Motil       Date:  2011-10-31       Impact factor: 4.924

9.  Irritable Bowel Syndrome Therapeutic Has Broad-Spectrum Antimicrobial Activity.

Authors:  Ashley L Cunningham; Orhi Esarte Palomero; Bradley J Voss; M Stephen Trent; Bryan W Davies
Journal:  Antimicrob Agents Chemother       Date:  2021-07-19       Impact factor: 5.191

Review 10.  Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review.

Authors:  John K Triantafillidis; George Malgarinos
Journal:  Clin Exp Gastroenterol       Date:  2014-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.